{"id":"https://openalex.org/W201601384","doi":null,"title":"Sodium-glucose cotransporter inhibitors for diabetes.","display_name":"Sodium-glucose cotransporter inhibitors for diabetes.","publication_year":2007,"publication_date":"2007-04-01","ids":{"openalex":"https://openalex.org/W201601384","mag":"201601384","pmid":"https://pubmed.ncbi.nlm.nih.gov/17458177"},"language":"en","primary_location":{"id":"pmid:17458177","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17458177","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045000792","display_name":"Masayuki Isaji","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119256","display_name":"Kissei Pharmaceutical (Japan)","ror":"https://ror.org/028gkfr23","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210119256"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Masayuki Isaji","raw_affiliation_strings":["Address Kissei Pharmaceutical Co Ltd, Central Research Laboratory, 4365-1 Kashiwabara, Hotaka, Azumino City, Nagano-Pref, Japan. masayuki_isaji@pharm.kissei.co.jp"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Address Kissei Pharmaceutical Co Ltd, Central Research Laboratory, 4365-1 Kashiwabara, Hotaka, Azumino City, Nagano-Pref, Japan. masayuki_isaji@pharm.kissei.co.jp","institution_ids":["https://openalex.org/I4210119256"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045000792"],"corresponding_institution_ids":["https://openalex.org/I4210119256"],"apc_list":null,"apc_paid":null,"fwci":6.066,"has_fulltext":false,"cited_by_count":87,"citation_normalized_percentile":{"value":0.96662466,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"8","issue":"4","first_page":"285","last_page":"92"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sglt2","display_name":"SGLT2","score":0.8100000023841858},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/diabetes-treatment","display_name":"diabetes treatment","score":0.6779999732971191},{"id":"https://openalex.org/keywords/renal-glucose-reabsorption","display_name":"renal glucose reabsorption","score":0.9279999732971191},{"id":"https://openalex.org/keywords/renal-glucose-excretion","display_name":"renal glucose excretion","score":0.8700000047683716},{"id":"https://openalex.org/keywords/blood-glucose-reduction","display_name":"blood glucose reduction","score":0.6930000185966492},{"id":"https://openalex.org/keywords/energy-balance","display_name":"energy balance","score":0.8479999899864197},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5149999856948853},{"id":"https://openalex.org/keywords/drug-potency","display_name":"drug potency","score":0.4390000104904175}],"concepts":[{"id":"https://openalex.org/C90466245","wikidata":"https://www.wikidata.org/wiki/Q7312490","display_name":"Renal glucose reabsorption","level":4,"score":0.9056405425071716},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6388962268829346},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6211320757865906},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.608475923538208},{"id":"https://openalex.org/C57476199","wikidata":"https://www.wikidata.org/wiki/Q7312501","display_name":"Renal sodium reabsorption","level":4,"score":0.5313924551010132},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5023128986358643},{"id":"https://openalex.org/C56906281","wikidata":"https://www.wikidata.org/wiki/Q4391435","display_name":"Reabsorption","level":3,"score":0.44703710079193115},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.42518821358680725},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.41932493448257446},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.41312333941459656},{"id":"https://openalex.org/C3018376624","wikidata":"https://www.wikidata.org/wiki/Q1100933","display_name":"Diabetes treatment","level":4,"score":0.4100337624549866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3537274897098541},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3139568865299225},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.30210790038108826},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13123592734336853},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002254","descriptor_name":"Carbonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002254","descriptor_name":"Carbonates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051247","descriptor_name":"Sodium-Glucose Transport Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:17458177","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17458177","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:201601384","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17458177","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2186788635","https://openalex.org/W1899807044","https://openalex.org/W3028739832","https://openalex.org/W2082229796","https://openalex.org/W2962742728","https://openalex.org/W2289654763","https://openalex.org/W2810443854","https://openalex.org/W2375046916","https://openalex.org/W1970063460","https://openalex.org/W2053560317"],"abstract_inverted_index":{"In":[0],"the":[1,9,21,35,67,77,94,103],"search":[2],"for":[3,8,102],"potential":[4,104],"new":[5],"drug":[6],"targets":[7],"treatment":[10,105],"of":[11,23,69,79,83,99,106],"diabetes,":[12],"sodium-glucose":[13],"cotransporters":[14],"(SGLTs),":[15],"in":[16,31,34,57],"particular":[17,24],"SGLT2,":[18],"have":[19,92],"been":[20],"subject":[22],"attention.":[25],"SGLT2":[26,38,51,64,88],"plays":[27],"an":[28],"important":[29],"role":[30],"glucose":[32,42,48],"reabsorption":[33],"kidney,":[36],"and":[37,44,90,97],"inhibitors":[39,52],"enhance":[40],"renal":[41],"excretion":[43],"consequently":[45],"lower":[46],"plasma":[47],"levels.":[49],"Thus,":[50],"can":[53],"control":[54],"energy":[55],"balance":[56],"a":[58],"negative":[59],"direction.":[60],"The":[61],"principle":[62],"behind":[63],"inhibition":[65],"involves":[66],"improvement":[68],"diabetic":[70],"conditions":[71],"without":[72],"increasing":[73],"body":[74],"weight":[75],"or":[76],"risk":[78],"hypoglycemia.":[80],"A":[81],"number":[82],"pharmaceutical":[84],"companies":[85],"are":[86],"evaluating":[87],"inhibitors,":[89],"studies":[91],"confirmed":[93],"therapeutic":[95],"potency":[96],"safety":[98],"these":[100],"drugs":[101],"diabetes.":[107]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}